Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
This article was originally published in The Pink Sheet Daily
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
You may also be interested in...
FDA officials attempt to clear up questions on regulatory expectations for qualifying raw materials for cell and gene therapy products. FDA officials advise manufacturers to conduct risk assessments, use the highest-grade materials they can find and avoid using animal-derived raw materials. Industry officials describe complexities in making these products.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.